← Back to news
NewsFRONTIERS IN IMMUNOLOGYFriday, March 6, 2026 · March 6, 2026

Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study.

WHY IT MATTERS

Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.

To investigate the efficacy and safety of telitacicept combined with glucocorticoid/mycophenolate mofetil (GM) versus telitacicept in the treatment of immunoglobulin A nephropathy (IgAN). This retrospective, multicenter cohort study enrolled patients aged ≥ 18 years with biopsy-proven IgAN wh...

Read on PubMed
Read the original at Frontiers in immunology
ResearchPubMedImmunoglobulin A nephropathyHumansGlomerulonephritis, IGA

Related conditions

Immunoglobulin A nephropathy

Related news

Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.